🚀 Apply for £10k+ grants with our Startup Launch Kit
shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)

    NOT-AI-25-034

    Rajeev Gautam, Ph.D. National Institute of Allergy and Infectious Disease (NIAID)

    Opening date 27 May 2025, 12:00AM

    Closing date N/A

    Funding Opportunity Number: NOT-AI-25-034

    Opportunity Category: Discretionary

    Expected Number of Awards: 4

    CFDA Number(s): 93.855 -- Allergy and Infectious Diseases Research

    Cost Sharing or Matching Requirement: No

    Posted Date: May 27, 2025 12:00:00 AM EDT

    Closing Date: N/A

    Estimated Total Program Funding: 8300000

    Eligible Applicants: Public housing authorities/Indian housing authorities,Native American tribal organizations (other than Federally recognized tribal governments),Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),State governments,Private institutions of higher education,For profit organizations other than small businesses,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Small businesses,County governments,Independent school districts

    Description:

    The National Institute of Allergy and Infectious Diseases intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to participate in a consortium of Research Centers focused on designing, optimizing, evaluating, and developing broadly protective vaccines for hepatitis C virus (HCV) to enable the advancement of vaccine candidates into clinical evaluation. This NOFO will utilize the U19 activity code.


    Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into this area of HCV vaccine development are encouraged to begin to consider applying for this new NOFO. In addition, collaborative investigations will be encouraged, and these investigators should also begin considering applying for this NOFO. 

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept